238 related articles for article (PubMed ID: 36890164)
21. Long-term risks of malignancy in myositis-specific antibody-positive idiopathic inflammatory myopathy.
Izuka S; Komai T; Shoda H; Fujio K
Rheumatol Int; 2023 Feb; 43(2):335-343. PubMed ID: 36175662
[TBL] [Abstract][Full Text] [Related]
22. Predictors and Mortality of Rapidly Progressive Interstitial Lung Disease in Patients With Idiopathic Inflammatory Myopathy: A Series of 474 Patients.
Li Y; Gao X; Li Y; Jia X; Zhang X; Xu Y; Gan Y; Li S; Chen R; He J; Sun X
Front Med (Lausanne); 2020; 7():363. PubMed ID: 32850886
[No Abstract] [Full Text] [Related]
23. Serological risk factors for concomitant interstitial lung disease in patients with idiopathic inflammatory myopathy.
Huang HL; Lin WC; Yeh CC; Sun YT
J Clin Neurosci; 2020 Apr; 74():32-35. PubMed ID: 31982271
[TBL] [Abstract][Full Text] [Related]
24. 18F-FDG PET/CT and HRCT: a combined tool for risk stratification in idiopathic inflammatory myopathy-associated interstitial lung disease.
Zhang Y; Chen Z; Long Y; Zhang B; He Q; Tang K; Zhang X
Clin Rheumatol; 2022 Oct; 41(10):3095-3105. PubMed ID: 35759126
[TBL] [Abstract][Full Text] [Related]
25. Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis.
Jin Q; Fu L; Yang H; Chen X; Lin S; Huang Z; Gao B; Tian X; Jiang W; Shu X; Lu X; Wang G; Peng Q
J Intern Med; 2023 Apr; 293(4):494-507. PubMed ID: 36682032
[TBL] [Abstract][Full Text] [Related]
26. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis.
So J; So H; Wong VT; Ho R; Wu TY; Wong PC; Tam LH; Ho C; Lam TT; Chung YK; Li WL; To CH; Lau CS; Mok CC; Tam LS
Rheumatology (Oxford); 2022 Nov; 61(11):4437-4444. PubMed ID: 35157042
[TBL] [Abstract][Full Text] [Related]
27. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
28. Myositis-Related Interstitial Lung Disease: A Respiratory Physician's Point of View.
Waseda Y
Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34200737
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis of myositis-associated interstitial lung disease: Utility of the myositis autoantibody line immunoassay.
Jee AS; Parker MJS; Bleasel JF; Troy LK; Lau EM; Jo HE; Teoh AKY; Webster S; Adelstein S; Corte TJ
Respir Med; 2021 Oct; 187():106581. PubMed ID: 34454312
[TBL] [Abstract][Full Text] [Related]
30. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.
Gono T; Kawaguchi Y; Satoh T; Kuwana M; Katsumata Y; Takagi K; Masuda I; Tochimoto A; Baba S; Okamoto Y; Ota Y; Yamanaka H
Rheumatology (Oxford); 2010 Sep; 49(9):1713-9. PubMed ID: 20498012
[TBL] [Abstract][Full Text] [Related]
31. Antibody predictors of mortality and lung function trends in myositis spectrum interstitial lung disease.
Hannah JR; Lawrence A; Martinovic J; Naqvi M; Chua F; Kouranos V; Ali SS; Stock C; Owens C; Devaraj A; Pollard L; Agarwal S; Atienza-Mateo B; González-Gay MA; Patel A; West A; Tinsley K; Robbie H; Lams B; Wells AU; Norton S; Galloway J; Renzoni EA; Gordon PA
Rheumatology (Oxford); 2023 Dec; ():. PubMed ID: 38039151
[TBL] [Abstract][Full Text] [Related]
32. Clinical Value of
Liang J; Cao H; Wu B; Liu Y; He Y; Xu B; Sun Y; Ye B; Lin J
Front Immunol; 2021; 12():745211. PubMed ID: 34867971
[TBL] [Abstract][Full Text] [Related]
33. A clinical analysis of risk factors for interstitial lung disease in patients with idiopathic inflammatory myopathy.
Cen X; Zuo C; Yang M; Yin G; Xie Q
Clin Dev Immunol; 2013; 2013():648570. PubMed ID: 24106519
[TBL] [Abstract][Full Text] [Related]
34. Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort.
Chua F; Higton AM; Colebatch AN; O'Reilly K; Grubnic S; Vlahos I; Edwards CJ; Kiely PD
Rheumatology (Oxford); 2012 Oct; 51(10):1870-6. PubMed ID: 22763991
[TBL] [Abstract][Full Text] [Related]
35. Systematic review and meta-analysis of prognostic factors for idiopathic inflammatory myopathy-associated interstitial lung disease.
Kamiya H; Panlaqui OM; Izumi S; Sozu T
BMJ Open; 2018 Dec; 8(12):e023998. PubMed ID: 30559160
[TBL] [Abstract][Full Text] [Related]
36. Prognostic evaluation of serum osteopontin in patients with anti-MDA5 antibody-positive dermatomyositis associated interstitial lung disease.
Gao Y; Zhao Q; Xie M; Yan X; Li Y; Zhang X; Wu H; Dai J; Cao M; Cai H
Cytokine; 2020 Nov; 135():155209. PubMed ID: 32738770
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic plasma exchange for steroid refractory idiopathic inflammatory myopathies with interstitial lung disease.
Thompson TZ; Bobr A; Juskewitch JE; Winters JL
J Clin Apher; 2023 Aug; 38(4):481-490. PubMed ID: 36408807
[TBL] [Abstract][Full Text] [Related]
38. Surfactant protein D is associated with 3-month mortality of anti-MDA5 antibody-interstitial lung disease.
Lyu W; Zhou Y; Zhuang Y; Liu Y; Cao M; Xin X; Wu H; Wang J; Meng F; Cai H; Dai J
Clin Exp Rheumatol; 2020; 38(6):1068-1074. PubMed ID: 31994487
[TBL] [Abstract][Full Text] [Related]
39. Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: A meta-analysis of 20 cohorts.
Zhong L; Yu Z; Song H
Clin Immunol; 2019 Jan; 198():11-18. PubMed ID: 30445156
[TBL] [Abstract][Full Text] [Related]
40. Serum levels of galectin-3 in idiopathic inflammatory myopathies: a potential biomarker of disease activity.
Watanabe E; Kato K; Gono T; Chiba E; Terai C; Kotake S
Rheumatology (Oxford); 2021 Jan; 60(1):322-332. PubMed ID: 32770187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
